Search

Your search keyword '"David Lavi"' showing total 30 results

Search Constraints

Start Over You searched for: Author "David Lavi" Remove constraint Author: "David Lavi" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
30 results on '"David Lavi"'

Search Results

1. Remote immune processes revealed by immune-derived circulating cell-free DNA

2. Impairments of interpersonal synchrony evident in attention deficit hyperactivity disorder (ADHD)

3. Changing Preference of One- Vs. Two-Stage Implant Placement in Partially Edentulous Individuals: An 18-Year Retrospective Study

4. Group G Streptococcal Bacteremia in Jerusalem

5. Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events

7. Influence of Vinyl Polysiloxane Impression Techniques on Marginal Fit of Metal Frameworks for Fixed Partial Dentures

8. Impairments of interpersonal synchrony evident in attention deficit hyperactivity disorder (ADHD)

9. Changing Preference of One- Vs. Two-Stage Implant Placement in Partially Edentulous Individuals: An 18-Year Retrospective Study

10. Bone Microstrain Values of 1-Piece and 2-Piece Implants Subjected to Mechanical Loading

11. S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

12. P1068: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

13. P1065: UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

15. P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

16. Retrospective Clinical Evaluation of Tapered Implants

18. Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib

19. Cardiovascular and bone health of former elite infantry soldiers at middle life

20. Group G Streptococcal Bacteremia in Jerusalem

21. Implementation of an organizational infrastructure paediatric plan adapted to bronchiolitis epidemics

23. P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

24. T058: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti–PD-1 Treatment

25. Anti-CK7/CK20 Immunohistochemistry Did Not Associate with the Metastatic Site in TTF-1-Negative Lung Cancer

26. Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis

27. Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma

28. #informetwitter: análisis cualitativo del usuario avanzado de la red social

29. Temperature Field Progression in Annular Tube Around Heated Rod in Respect to the Mass Flow of Coolant

Catalog

Books, media, physical & digital resources